银屑病与肥胖相关性的研究进展

doi:10.35541/cjd.20200063

Abstract

Abstract: 【Abstract】 It has become a consensus that there is a correlation between psoriasis and obesity, but the exact mechanism is not yet clear. Studies demonstrate that common inflammatory pathways and insulin resistance may contribute to the association between psoriasis and obesity. Understanding the impact of obesity on the occurrence and treatment of psoriasis will be beneficial to the treatment of psoriasis.

Key words: Psoriasis, Obesity, Insulin resistance, Therapy, Inflammatory mediator

Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity[J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.doi:10.35541/cjd.20200063

References ［38］

［1］	Snekvik I, Nilsen T, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT study, Norway［J］. Br J Dermatol, 2019,180（1）:94⁃99. doi: 10.1111/bjd.16885.
［2］	Shreberk⁃Hassidim R, Galili E, Hassidim A, et al. Epidemiology and comorbidities of psoriasis among Israeli adolescents: a large cross⁃sectional study［J］. Dermatology, 2019,235（6）:488⁃494. doi: 10.1159/000501032.
［3］	Aune D, Snekvik I, Schlesinger S, et al. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose⁃response meta⁃analysis of prospective studies［J］. Eur J Epidemiol, 2018,33（12）:1163⁃1178. doi: 10.1007/s10654⁃018⁃0366⁃z.
［4］	Kunz M, Simon JC, Saalbach A. Psoriasis: obesity and fatty acids［J］. Front Immunol, 2019,10:1807. doi: 10.3389/fimmu.2019. 01807.
［5］	Tupikowska⁃Marzec M, Kolačkov K, Zdrojowy⁃Wełna A, et al. The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis［J］. Biomed Res Int, 2019,2019:7304345. doi: 10.1155/2019/7304345.
［6］	Loft ND, Skov L, Rasmussen MK, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis［J］. PLoS One, 2018,13（2）:e0192010. doi: 10.1371/journal.pone.0192010.
［7］	Yu GI, Ha E, Park SH, et al. Association of tumor necrosis factor⁃α （TNF⁃α） promoter polymorphisms with overweight/obesity in a Korean population［J］. Inflamm Res, 2011,60（12）:1099⁃1105. doi: 10.1007/s00011⁃011⁃0372⁃z.
［8］	Shiao S, Xiao H, Dong L, et al. Genome wide DNA differential methylation regions in colorectal cancer patients in relation to blood related family members, obese and non⁃obese controls ⁃ a preliminary report［J］. Oncotarget, 2018,9（39）:25557⁃25571. doi: 10.18632/oncotarget.25374.
［9］	Hodeib AA, Neinaa Y, Zakaria SS, et al. Glucose transporter⁃1 （GLUT⁃1） expression in psoriasis: correlation with disease severity［J］. Int J Dermatol, 2018,57（8）:943⁃951. doi: 10.1111/ijd.14037.
［10］	Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment［J］. J Dermatol, 2018,45（3）:264⁃272. doi: 10.1111/1346⁃8138.14139.
［11］	Francisco V, Pino J, Campos⁃Cabaleiro V, et al. Obesity, Fat mass and immune system: role for leptin［J］. Front Physiol, 2018,9:640. doi: 10.3389/fphys.2018.00640.
［12］	Zhang Y, Yuan H, Bu P, et al. Recombinant leptin attenuates abdominal aortic aneurysm formation in angiotensin II⁃infused apolipoprotein E⁃deficient mice［J］. Biochem Biophys Res Commun, 2018,503（3）:1450⁃1456. doi: 10.1016/j.bbrc.2018.07. 062.
［13］	Han JH, Lee JH, Han KD, et al. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population⁃based study［J］. J Dermatol, 2019,46（8）:695⁃701. doi: 10.1111/1346⁃8138.14939.
［14］	Bavoso NC, Pinto JM, Soares M, et al. Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects ⁃ cases and controls［J］. An Bras Dermatol, 2019,94（2）:192⁃197. doi: 10.1590/abd1806⁃4841.20197716.
［15］	Nicolas S, Chabry J, Guyon A, et al. Adiponectin: an endogenous molecule with anti⁃inflammatory and antidepressant properties?［J］. Med Sci （Paris）, 2018,34（5）:417⁃423. doi: 10.1051/medsci/ 20183405014.
［16］	Buechler C, Feder S, Haberl EM, et al. Chemerin isoforms and activity in obesity［J］. Int J Mol Sci, 2019,20（5）. doi: 10.3390/ijms20051128.
［17］	王媛, 张鼎伟, 霍佳, 等. Chemerin/chemR23对银屑病患者外周血Th9/Treg细胞平衡的影响［J］. 中南大学学报（医学版）, 2019,44（2）:144⁃149. doi: 10.11817/j.issn.1672⁃7347.2019.02. 005.
［18］	Kumari B, Yadav U. Adipokine visfatin′s role in pathogenesis of diabesity and related metabolic derangements［J］. Curr Mol Med, 2018,18（2）:116⁃125. doi: 10.2174/15665240186661807 05114131.
［19］	Chyl⁃Surdacka KM, Bartosińska J, Kowal M, et al. Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities［J］. Adv Clin Exp Med, 2020,29（1）:79⁃84. doi: 10.17219/acem/111820.
［20］	Kwanbunjan K, Panprathip P, Phosat C, et al. Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk［J］. BMC Endocr Disord, 2018,18（1）:26. doi: 10.1186/s12902⁃018⁃0254⁃2.
［21］	Wang HM, Wu C, Jiang YY, et al. Retinol and vitamin a metabolites accumulate through RBP4 and STRA6 changes in a psoriasis murine model［J］. Nutr Metab （Lond）, 2020,17:5. doi: 10.1186/s12986⁃019⁃0423⁃y.
［22］	Hu Y, Zhu Y, Lian N, et al. Metabolic syndrome and skin diseases［J］. Front Endocrinol （Lausanne）, 2019,10:788. doi: 10.3389/fendo.2019.00788.
［23］	Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target［J］. Front Immunol, 2018,9:2786. doi: 10.3389/fimmu.2018.02786.
［24］	Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes［J］. Int J Biol Sci, 2018,14（11）:1483⁃1496. doi: 10.7150/ijbs.27173.
［25］	Cataldi C, Mari NL, Lozovoy M, et al. Proinflammatory and anti⁃inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors［J］. Inflamm Res, 2019,68（7）:557⁃567. doi: 10.1007/s00011⁃019⁃01238⁃8.
［26］	Karczewski J, Śledzińska E, Baturo A, et al. Obesity and inflammation［J］. Eur Cytokine Netw, 2018,29（3）:83⁃94. doi: 10.1684/ecn.2018.0415.
［27］	Singh S, Facciorusso A, Singh A G, et al. Obesity and response to anti⁃tumor necrosis factor⁃α agents in patients with select immune⁃mediated inflammatory diseases: a systematic review and meta⁃analysis［J］. PLoS ONE, 2018,13（5）:e0195123. doi: 10.1371/ journal.pone.0195123.
［28］	Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials［J］. Cureus, 2018,10（10）:e3491. doi: 10.7759/cureus.3491.
［29］	Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents［J］. J Am Acad Dermatol, 2019,80（1）:27⁃40. doi: 10.1016/j.jaad.2018.06.057.
［30］	Hong JR, Lee YW, Choe YB, et al. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real⁃world practice［J］. Dermatol Ther, 2019,32（3）:e12875. doi: 10.1111/dth.12875.
［31］	Storan ER, Galligan J, Barnes L. Phototherapy⁃induced erythema in patients with psoriasis and obesity treated with narrowband UVB phototherapy［J］. Photodermatol Photoimmunol Photomed, 2014,30（6）:335⁃337. doi: 10.1111/phpp.12121.
［32］	Vujic I, Herman R, Sanlorenzo M, et al. Apremilast in psoriasis ⁃ a prospective real⁃world study［J］. J Eur Acad Dermatol Venereol, 2018,32（2）:254⁃259. doi: 10.1111/jdv.14598.
［33］	Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co⁃morbid psoriasis and obesity?［J］. Expert Opin Pharmacother, 2019,20（11）:1303⁃1308. doi: 10.1080/14656566.2019.1603294.
［34］	Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity［J］. Expert Opin Pharmacother, 2019,20（7）:863⁃872. doi: 10.1080/14656566.2019.1583207.
［35］	Yang J, Wang Z, Zhang X. GLP⁃1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK［J］. Exp Mol Pathol, 2019,107:124⁃128. doi: 10.1016/j.yexmp.2019.01. 014.
［36］	Ba W, Xu Y, Yin G, et al. Metformin inhibits pro⁃inflammatory responses via targeting nuclear factor⁃κB in HaCaT cells［J］. Cell Biochem Funct, 2019,37（1）:4⁃10. doi: 10.1002/cbf.3367.
［37］	Ba W, Xu Y, Yin G, et al. Metformin inhibits pro⁃inflammatory responses via targeting nuclear factor⁃κB in HaCaT cells［J］. Cell Biochem Funct, 2019,37（1）:4⁃10. doi: 10.1002/cbf.3367.
［38］	Chang G, Wang J, Song J, et al. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta⁃analysis of randomized controlled trials［J］. J Dermatolog Treat, 2019:1⁃7. doi: 10.1080/09546634.2019.1610552.

[1]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[2]	Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220140-e20220140.
[3]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[4]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220337-e20220337.
[5]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[6]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[7]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[8]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[9]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.
[10]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.
[11]	Tian Jing, Liang Yuan, Ma Lin. Dupilumab in the treatment of childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210730-e20210730.
[12]	Li Tingting, Kang Xiaojing. Gut microbiota and immune checkpoint inhibitor treatment of melanoma [J]. Chinese Journal of Dermatology, 2023, 56(2): 177-180.
[13]	Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210536-e20210536.
[14]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[15]	Jia Yuanyuan, Mao Qiuyu, Yang Jingyi, Min Wei. Efficacy of dupilumab in the treatment of moderate and severe atopic dermatitis in the elderly: a clinical observation [J]. Chinese Journal of Dermatology, 2023, 56(2): 125-129.

Correlations between psoriasis and obesity

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［38］

Related Articles 15

Metrics

Comments

Recommended 10